Protein N-Glycosylation Traits Combined with CA19-9 Accurately Distinguish Pancreatic Cancer Cases From Healthy Controls and Benign Pancreatic Diseases.

ABSTRACT:

Objectives

New methods are needed to detect pancreatic ductal adenocarcinoma (PDAC) earlier to improve outcomes. We previously reported that a panel of protein N-glycosylation traits (NGTs) discriminated PDAC from healthy-controls with an area under the curve (AUC) of 0.81-0.88. However, it remained unclear whether this panel accurately differentiates PDAC from other benign pancreatic disorders. Our study aims to evaluate the performance of the NGT panel in combination with CA19-9, in a diverse cohort, including PDAC cases, healthy-controls and controls with benign pancreatic disorders.

Methods

Protein N-glycosylation profiles were determined in plasma samples using an in-house developed mass spectrometry assay. CA19-9 levels were measured using routine immunoassay test. Res

SUBMITTER: Bogdanski AM 

PROVIDER: S-EPMC12419019 | biostudies-literature | 2025 May

REPOSITORIES: biostudies-literature